P1006: CHARACTERIZATION OF TL-895: A NOVEL BRUTON TYROSINE KINASE INHIBITOR (BTKI) IN CLINICAL DEVELOPMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MYELOFIBROSIS (MF)

por Gulrajani, Michael, Clevenger, Tracy, Cheung, Jean, Krantz, Fanny, Nguyen, Cynthia, Luarca, Miranda, Krejsa, Cecile, Rothbaum, Wayne P., Covey, Todd
Publicado 2023

P991: ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) POTENTIATES APOPTOSIS IN MYELOBLASTS FROM PATIENTS (PTS) WITH MYELOFIBROSIS (MF)

por Clevenger, Tracy, Cheung, Jean, Krantz, Fanny, Gulrajani, Michael, Nguyen, Cynthia, Luarca, Miranda, Krejsa, Cecile, Rothbaum, Wayne P., Covey, Todd
Publicado 2023

P1005: EFFECT OF TL-895, A NOVEL BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ON ONCOGENIC JANUS KINASE 2-V617F (JAK2VF) SIGNALING

por Chary Nimmagadda, Subbaiah, Marie Budde, Paulina, Sun, Kaiyan, Covey, Todd, Krejsa, Cecile, Rothbaum, Wayne P., von Bubnoff, Nikolas, Khandanpour, Cyrus
Publicado 2023

Distinct Patterns of DNA Damage Response and Apoptosis Correlate with Jak/Stat and PI3Kinase Response Profiles in Human Acute Myelogenous Leukemia

por Rosen, David B., Putta, Santosh, Covey, Todd, Huang, Ying-Wen, Nolan, Garry P., Cesano, Alessandra, Minden, Mark D., Fantl, Wendy J.
Publicado 2010

The role of the DNA damage response in zebrafish and cellular models of Diamond Blackfan anemia

por Danilova, Nadia, Bibikova, Elena, Covey, Todd M., Nathanson, David, Dimitrova, Elizabeth, Konto, Yoan, Lindgren, Anne, Glader, Bertil, Radu, Caius G., Sakamoto, Kathleen M., Lin, Shuo
Publicado 2014

Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma

por Harrington, Bonnie K., Gardner, Heather L., Izumi, Raquel, Hamdy, Ahmed, Rothbaum, Wayne, Coombes, Kevin R., Covey, Todd, Kaptein, Allard, Gulrajani, Michael, Van Lith, Bart, Krejsa, Cecile, Coss, Christopher C., Russell, Duncan S., Zhang, Xiaoli, Urie, Bridget K., London, Cheryl A., Byrd, John C., Johnson, Amy J., Kisseberth, William C.
Publicado 2016